aripiprazole in the maintenance treatment of bipolar disorder a critical review of the evidence and its dissemination into the scientific literature阿立哌唑的维持治疗双相情感障碍的关键审查证据及其传播科学文献.pdf

Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature 1. 2. 3 4 5 Alexander C. Tsai *, Nicholas Z. Rosenlicht , Jon N. Jureidini , Peter I. Parry , Glen I. Spielmans , David Healy6 1 Robert Wood Johnson Health and Society Scholars Program, Harvard University, Cambridge, Massachusetts, United States of America, 2 Department of Psychiatry, University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America, 3 Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia, Australia, 4 Child and Adolescent Mental Health Service, Division of Mental Health, Flinders University, Adelaide, South Australia, Australia, 5 Department of Psychology, Metropolitan State University, St. Paul, Minnesota, United States of America, 6 Department of Psychological Medicine, Cardiff University, Cardiff, Wales, United Kingdom Abstract Background: Aripiprazole, a second-generation antipsychotic medication, has been increasingly used in the maintenance treatment of bipolar disorder and received approval from the U.S. Food and Drug Administration for this indication in 2005. Given its widespread use, we sought to critically review the evidence supporting the use of aripiprazole in the maintenance treatment of bipolar disorder and examine how that evidence has been disseminated in the scientific literature. Methods and Findings: We systematically searched multiple databases to identify double-blind, randomized controlled trials of aripiprazole for the maintenance treatment of bipolar disorder while excluding other types of studies, such as op